Federal News Update: NIH Funding, Vaccine Policy and Looming Drug Pricing Deadline
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC Launches “Access Granted”
Access Granted is the Association of Multisite Research Corporations’s (AMRC) initiative for increasing site participation at industry events. This month, we are giving away five free tickets to the inaugural Partnerships with Sites Summit, 15 September 2025, Philadelphia by entering our free prize giveaway.
AMRC Federal Update, 6-24-25
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
Jennifer Byrne joins AMRC Board of Directors
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
As Pharma Pricing Pressures Hit All-Time High, MCRCs are Uniquely Positioned to Help
The word ‘bipartisan’ might have been sparsely used since January, but the issue of drug pricing has permeated both sides of the aisle over the last three years. The Biden Administration’s Inflation Reduction Act of 2022 marked a policy shift that empowered Medicare to re-negotiate pricing on some high-cost drugs for the first time. The Trump administration also signalled its stance on the issue last week, introducing a ‘Most Favored Nation’ (MFN) pricing model by way of executive order.
Member Spotlight: ALCANZA Clinical Works to Extend ‘Reach’ of Clinical Trials
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC welcomes Pratia as newest member, strengthening European representation
The Association of Multisite Research Corporations (AMRC) today announces Pratia, one of the largest and most respected site networks, has joined as the association’s fifteenth member. With this addition, AMRC now represents a collective footprint of nearly 500 research sites, almost 8,000 employees, and approximately 1,500 principal investigators across its member companies, globally.
Webinar Summary: Capitol Hill Forecast — What Should MCRCs Prepare For?
Hosted by AMRC, this timely webinar offered insights into the evolving federal policy and funding landscape affecting multisite clinical research corporations (MCRCs), with a strong focus on strategic advocacy and the challenges ahead.
Member Spotlight: Helios on patient-centered oncology care and addressing ‘One-and-Done’
In a recent interview with E.B. McLindon, CEO of Helios Clinical Research and Director at the Association for Multi-Site Research Corporations (AMRC), McLindon shared his perspective on the mindset needed in the research industry
AMRC responds to an FDA consultation
As part of AMRC’s role to advocate for multisite clinical research corporations (MCRC), we responded to the FDA’s consultation: Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices; Guidance for Industry – Draft Guidance.
